- Home
Clinical trials - page 6

Search for a clinical trial
Filter
Filter
Geographical location
Type of cancer
Refine your search
Age
Phase
Search for a clinical trial
195 result(s)
- SarcomasParisPM1183-C-010-22Phase IIb/III, randomized, controlled, open-label study to evaluate lurbinectedin in combination with;doxorubicin versus doxorubicin monotherapy as first-line treatment in patients;suffering from metastatic leiomyosarcoma.
SARAH WATSON
- Paris, Saint-CloudPOP-ARTA Phase I Study on Tuvusertib (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients;with advanced solid tumors.
FRANCOIS-CLEMENT BIDARD
- Breast cancerParisPRETORIAPROSPECTIVE EVALUATION OF A PREDICTIVE TOXICITY TEST POST RADIOTHERAPY AFTER MASTECTOMY WITH IMMEDIATE IMPLANT RECONSTRUCTION.
YOULIA KIROVA
- Childhood and adolescent cancersParisPROVINStudy of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors (PROVIN)
ISABELLE AERTS GAJDOS
- SarcomasSaint-CloudPRT2527-02A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies.
CLEMENTINE SARKOZY
- Digestive cancersParis, Saint-CloudProActIF-01ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers
TIMOTHEE MARCHAL
- Saint-CloudQPL-MDSEvaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)
SANDRA MALAK
- Lung cancerParisR2810-ONC-2268A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE;CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS;CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE;PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE;NON-SMALL CELL LUNG CANCER;SUBPROTOCOL 1: REGN7075
NICOLAS GIRARD
- MyélomeSaint-CloudR5458-ONC-2245An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; anti-;BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab,;Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory;Multiple Myeloma (LINKER-MM3).
Cyrine ELLOUZ
- Thymic tumorsParisRADIO-RYTHMIC-01 (IC 2020-09)Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma
NICOLAS GIRARD
- Cancers gynécologiquesParisRAINBORefining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials · p53abn - RED.
AUDREY BELLESOEUR
- Childhood and adolescent cancersParisRETINO-2018 (IC 2019-05)Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018
LIVIA LUMBROSO-LE ROUIC
- Lung cancerParisRMC-LUNG-101Phase 1b/2 Open-Label, Multicenter Study of RMC-6291 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with KRASG12C-Mutated Solid Tumors
PAULINE DU RUSQUEC
- Cancers gynécologiquesParisROCSANA multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy
AUDREY BELLESOEUR
- Saint-CloudRTEP7 (IFCT-1402)Randomized Phase II-III Study of Personalized Radiotherapy Dose Redistribution in Patients With Inoperable Stage III Non-small Cell Lung Cancer and a Persistent FDG Uptake at 42 Grays During Concomitant Radio-chemotherapy.
MARIE ANGE MASSIANI
- Saint-CloudSAFIR ABC10Clinical trial of precision medicine in patients with advanced biliary tract cancers (cholangiocarcinoma or gallbladder cancer).
- Eye tumors / Uveal melanomaParisSALOME / IC 2019-13Follow-up of patients with uveal melanoma adapted to the risk of relapse.
SOPHIE PIPERNO-NEUMANN
- Cancer de l'ovaireParis, Saint-CloudSALVOVARA pragmatic randomized phase III trial to assess the utility of adjusting;chemotherapy dose & dosing schedule with the SALVage weekly dose-dense;regimen in patients with poor prognostic OVARian cancers based on the tumor;unfavorable primary chemosensitivity and incomplete debulking surgery.
CLEMENT BONNET
- Paris, Saint-CloudSCANDARE (IC 2016-03)Prospective biobanking study in ovarian, breast and head and neck cancer patients aiming at better understand the link between the molecular alterations of the tumor itself, its microenvironment and immune response.
CHRISTOPHE LE TOURNEAU
- Saint-CloudSERENA-4SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
FRANCOIS-CLEMENT BIDARD
- Childhood and adolescent cancersParisSIOP EPENDYMOMA IIAn International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma
FRANCOIS DOZ
- Breast cancerParis, Saint-CloudSKYLINETiragolumab, atezolizumab and chemotherapy in triple negative breast cancer:;A phase II trial.
FRANCOIS-CLEMENT BIDARD
- Saint-CloudSTARTA Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recurrent (Unresectable) or Metastatic Breast Cancer Treated With Darolutamide or Capecitabine
FLORENCE LEREBOURS
- Saint-CloudSTERIMGLIA Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI).
- SarcomasParisSTRASS 2 - ETUDE 1809-STBSGA randomized phase III study of neoadjuvant chemotherapy;followed by surgery versus surgery alone for patients with;High Risk RetroPeritoneal Sarcoma (STRASS 2)
SYLVIE BONVALOT
- Saint-CloudSUMMIT- PUMA-NER-0502An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.
FRANCOIS-CLEMENT BIDARD
- ENT/Head and Neck CancersParis, Saint-CloudSURVEILLE HPVNational, multicentre, open-label, randomised, phase II study evaluating HPV circulating DNA as biomarker to detect the recurrence, in order to improve post therapeutic surveillance of HPV-driven oropharyngeal cancers.
JOEY MARTIN
- Childhood and adolescent cancersParisSelupassPost-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study
ISABELLE AERTS GAJDOS
- SarcomasParisTANGENT (SNX-301-020)A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.
SOPHIE PIPERNO-NEUMANN